Glycogen synthase kinase-3 beta

GSK3B
Identifiers
AliasesGSK3B, Gsk3b, 7330414F15Rik, 8430431H08Rik, C86142, GSK-3, GSK-3beta, GSK3, glycogen synthase kinase 3 beta
External IDsOMIM: 605004; MGI: 1861437; GeneCards: GSK3B
Available structures
PDBOrtholog search: PDBe RCSB
Enzyme activity
EC #BRENDAExPASyKEGGMetaCyc
2.7.11.1↗↗↗↗
2.7.11.26↗↗↗↗
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001146156
NM_002093
NM_001354596

NM_019827
NM_001347232

RefSeq (protein)

NP_001139628
NP_002084
NP_001341525

NP_001334161
NP_062801

Location (UCSC)Chr 3: 119.82 – 120.09 MbChr 16: 37.91 – 38.07 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse

Glycogen synthase kinase-3 beta, (GSK-3 beta), is an enzyme that in humans is encoded by the GSK3B gene. In mice, the enzyme is encoded by the Gsk3b gene. Abnormal regulation and expression of GSK-3 beta is associated with an increased susceptibility towards bipolar disorder.

Function

Glycogen synthase kinase-3 (GSK-3) is a proline-directed serine-threonine kinase that was initially identified as a phosphorylating and an inactivating agent of glycogen synthase. Two isoforms, alpha (GSK3A) and beta, show a high degree of amino acid homology.

GSK3B is involved in energy metabolism, neuronal cell development, and body pattern formation.

Disease relevance

Homozygous disruption of the Gsk3b locus in mice results in embryonic lethality during mid-gestation. This lethality phenotype could be rescued by inhibition of tumor necrosis factor.

Two SNPs at this gene, rs334558 (-50T/C) and rs3755557 (-1727A/T), are associated with efficacy of lithium treatment in bipolar disorder.

Signaling pathways

Pharmacological inhibition of ERK1/2 restores GSK-3 beta activity and protein synthesis levels in a model of tuberous sclerosis.

Interactions

GSK3B has been shown to interact with:

Overview of signal transduction pathways involved in apoptosis.

See also